Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 1,738 trials

Cell Therapy for Amyotrophic Lateral Sclerosis

We are investigating whether a new cell therapy can help patients with ALS. This study aims to explore its effects on disease progression and quality of life.

Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)Neurology

Recurrent Diverticulitis: MBK-01 Capsules

We are studying whether MBK-01, a new intestinal microbiota capsule, can help reduce episodes of recurrent diverticulitis. The trial will also assess its safety and find the best dosage for patients.

Acute Diverticulitis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesGastroenterology

Advanced Solid Tumors: Testing IPN01194

We are studying a new drug, IPN01194, for adults with advanced solid tumors to see how safe it is and how well it works. This trial aims to understand its effects when used alone.

MelanomaPancreatic Ductal AdenocarcinomaColorectal Cancer≤3 monthsSafety phase (I)Efficacy phase (II)No PlaceboCost ReimbursementOncology

Becker Muscular Dystrophy: EDG-5506 Treatment Study

We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.

Becker's Muscular Dystrophy>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Clostridioides difficile Infection: EXL01 Treatment

We are studying a new oral treatment, EXL01, to see if it can help prevent the return of Clostridioides difficile infection in high-risk patients. The trial will evaluate its safety and effectiveness, along with its impact on digestive health and quality of life.

Recurrent Clostridioides difficile Infection>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesGastroenterologyInfectious Diseases

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology

Radiprodil for Seizures in Tuberous Sclerosis and Focal Cortical Dysplasia

We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.

Focal Cortical Dysplasia (FCD)Tuberous Sclerosis Complex (TSC)3-6 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Suicidal Thoughts: Nitrous Oxide Treatment in Emergencies

We are studying whether inhaling a mix of nitrous oxide and oxygen can reduce suicidal thoughts in patients at emergency departments. The trial also looks at its effects on anxiety and depression symptoms over time.

Suicidal Thoughts≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

MB-CART2019.1 Therapy for Pediatric B-Cell Neoplasms

We are studying how safe and effective MB-CART2019.1 is for children and teens with relapsed or refractory B-cell cancers. This research aims to find better treatment options for those who haven't responded to other therapies.

Refractory or Recurrent B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Uterine Leiomyosarcoma: Post-Operative Chemotherapy Study

We are investigating whether adding chemotherapy after surgery helps patients with high-risk localized uterine leiomyosarcoma avoid relapse. This study compares the new treatment approach to standard observation care.

Uterine LeiomyosarcomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Tourette Disorder: Serotonin and Impulsivity Study

We are investigating how serotonin receptors relate to impulsivity in adults with Tourette's syndrome. This study may help us understand brain activity and behavior during treatment.

Tourette Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

Bladder Cancer: Pembrolizumab and Enfortumab Combination

We are studying a combination of two medications for patients with first-line metastatic urothelial carcinoma. The aim is to evaluate their safety and effectiveness in treating this advanced cancer.

Bladder CancerSafety phase (I)Efficacy phase (II)Oncology

Advanced Urothelial Carcinoma: MK-2870 with Enfortumab Vedotin

We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.

Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Immuno-OCT Imaging: Safety and Feasibility Study

We are exploring a new imaging technique using a tracer for patients undergoing endoscopy. The goal is to determine if this method is safe and effective for better visualization during procedures.

Barrett's EsophagusColon CarcinomaGastrointestinal DysplasiaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Melanoma, NSCLC, and Cervical Cancer: ANV419 vs High-Dose IL-2

We are studying whether a new treatment (ANV419) is safer and improves outcomes compared to high-dose IL-2 for patients after tumor-infiltrating lymphocyte therapy. This trial also looks at quality of life and patient experiences.

Advanced Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Chronic Kidney Disease: FINESSE Study on Albuminuria Reduction

We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Ulcerative Colitis: Comparing Ustekinumab and Infliximab

We are studying whether a combination of two treatments helps people with moderate to severe ulcerative colitis achieve remission better than using each treatment alone.

Ulcerative Colitis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics